Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

27.05
+2.9912.43%
Post-market: 26.94-0.1100-0.41%19:57 EST
Volume:3.31M
Turnover:87.43M
Market Cap:5.45B
PE:-9.58
High:27.35
Open:26.88
Low:24.85
Close:24.06
52wk High:27.80
52wk Low:12.72
Shares:201.48M
Float Shares:93.92M
Volume Ratio:2.07
T/O Rate:3.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8237
EPS(LYR):-2.7303
ROE:-95.93%
ROA:-55.42%
PB:10.49
PE(LYR):-9.91

Loading ...

Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position

Stock Track
·
Yesterday

Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position

Stock Track
·
Yesterday

Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss

MT Newswires Live
·
Yesterday

Immunovant Q3 net loss smaller than expected

Reuters
·
Yesterday

Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate

Benzinga
·
Yesterday

BRIEF-Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million

Reuters
·
Yesterday

Immunovant Q3 Basic EPS USD -0.61

THOMSON REUTERS
·
Yesterday

Immunovant Q3 Net Income USD -110.635 Million VS. Ibes Estimate USD -125.1 Million

THOMSON REUTERS
·
Yesterday

Immunovant Q3 Operating Expenses USD 114.362 Million

THOMSON REUTERS
·
Yesterday

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

THOMSON REUTERS
·
Yesterday

Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish

Earnings Agent
·
Jan 30

Immunovant Inc. to Announce Third Quarter Financial Results and Business Update

Reuters
·
Jan 26

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Jan 15

Immunovant price target raised to $22 from $16 at Truist

TIPRANKS
·
Jan 08

Immunovant Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
Jan 06

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Dec 30, 2025

Immunovant (IMVT): Reassessing Valuation After a $550 Million Follow-On Equity Raise

Simply Wall St.
·
Dec 21, 2025

Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant Sciences - What's Changed

Simply Wall St.
·
Dec 15, 2025

Immunovant (IMVT): Reassessing Valuation After $550 Million Follow-On Offering for IMVT-1402 Launch

Simply Wall St.
·
Dec 12, 2025

Immunovant Inc - Files for Offering of 26,200,000 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Dec 12, 2025